drug
adalimumab
Marketedupdated 6mo agoby $ABBV AbbVie Inc.
Approvedannual revenue · 2024–2024peak $9.0B
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval432 co-mentions · 155 sources
- drugHUMIRA359 co-mentions · 156 sources
- drugAMJEVITA168 co-mentions · 94 sources
- drugABRILADA156 co-mentions · 88 sources
- drugYUSIMRY152 co-mentions · 86 sources
- company$ABBVAbbVie Inc.122 co-mentions · 61 sources
- drugYUFLYMA28 co-mentions · 14 sources
- drugHADLIMA26 co-mentions · 13 sources
Antibody drug with a maximum clinical stage of Approval (across all indications), with 14 approved and 20 investigational indications.
indications
investigational
IBD (Crohn's + UC)Rheumatoid Arthritis
all catalysts(61)
approval · 61
Dec 31, 2002
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 12, 2003
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jun 18, 2004
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jul 30, 2004
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Oct 3, 2005
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Oct 3, 2005
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jun 23, 2006
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jul 28, 2006
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Nov 9, 2006
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Nov 9, 2006
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Feb 16, 2007
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Feb 27, 2007
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jul 30, 2007
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 5, 2007
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jan 18, 2008
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Feb 21, 2008
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Mar 11, 2009
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Apr 8, 2010
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jul 29, 2010
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 29, 2010
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Nov 18, 2010
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Feb 25, 2011
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Mar 14, 2011
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jul 13, 2011
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 7, 2011
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Dec 13, 2011
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Dec 26, 2011
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
May 24, 2012
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 28, 2012
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Apr 24, 2013
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
May 13, 2013
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 19, 2013
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Feb 26, 2014
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
May 14, 2014
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
May 30, 2014
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Aug 7, 2014
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 23, 2014
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 30, 2014
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Oct 29, 2014
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Nov 6, 2014
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Dec 24, 2014
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 9, 2015
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Nov 23, 2015
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jun 30, 2016
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Oct 17, 2016
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Mar 27, 2017
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Apr 21, 2017
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Apr 28, 2017
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Dec 14, 2017
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Aug 2, 2018
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 28, 2018
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Oct 16, 2018
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Dec 6, 2018
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jan 11, 2019
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Mar 11, 2020
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Dec 16, 2020
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Dec 16, 2020
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Feb 24, 2021
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Nov 3, 2023
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jul 16, 2025
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Dec 23, 2025
approval
$ABBV286.01-2.33%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Trials studying adalimumab
- phase1A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the Colon
- phase4A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease
- phase3A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
- phase3Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
- phase1A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects
- phase4A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis
- phase4A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- phase3A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
News(10)
- Deaths, failed trials and other recent setbacks in the autoimmune spaceNovartis, Bristol Myers Squibb, argenx and more have recently been hit with challenges as they attempt to advance assets targeting autoimmune diseases, with some programs being axed entirely while…biospace · 3d ago
- AbbVie pens $1.4B deal for deprioritized IBD drug from NxeraAbbVie has added another angle to its relationship with Nxera, with the Big Pharma paying $100 million upfront for a phase 1 inflammatory bowel disease candidate.fiercebiotech · 15d ago
- AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on dealsStrong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit all-time highs.biospace · 19d ago
- 5 new drug launches that defied industry expectationsA clearly superior clinical profile, reasonable pricing and easy access has helped a handful of recently approved therapies achieve impressive launches.biospace · 22d ago
- AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectationsAbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late-stage trial, but the results have disappointed some analysts, raising q…biospace · 27d ago
- Roivant's TYK2/JAK inhibitor reduces need for steroids in inflammatory eye diseaseBrepocitinib is on a roll. After winning approval for an autoimmune skin disease, Roivant Sciences subsidiary Priovant’s drug hit all primary and secondary endpoints in a pair of Phase 3 non-infect…biospace · 28d ago
- Celltrion picks up another Kaigene autoimmune antibody for up to $580.5MCelltrion has licensed a preclinical antibody targeting autoimmune conditions from Maryland-based biotech Kaigene in a deal worth up to $580.5 million, marking another step in the South Korean drug…fiercebiotech · 28d ago
- Roivant, continuing ascent, claims another victory for rare disease drugShortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also be a “best-in-disease” medicine for an inflammatory eye condition, one an…biopharma_dive · 28d ago
- STAT+: Roivant says closely watched immune drug succeeded in new eye diseaseAn immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease non-infectious uveitis.stat · 29d ago
- As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune visionAbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster ca…biospace · 1mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that